

Electro-Magnetic-Frequency Therapy (EMF) for Chronic Fatigue

ACTRN12624000178549

Status RECRUITING
Sponsor AProf Dr Karin Ried
Enrollment 100 participants

Plain Language Summary

Chronic fatigue — particularly when linked to the reactivation of dormant viruses such as Epstein-Barr virus (the cause of glandular fever), cytomegalovirus, or herpes simplex virus — can be profoundly debilitating. Despite how common it is, treatment options remain limited and poorly understood. This study investigates whether electromagnetic frequency (EMF) therapy can reduce viral reactivation and improve symptoms.

Participants start with a 60 to 90-minute EMF session, and blood tests measure viral reactivation levels before and one day after. If the results are promising, a 12-week treatment plan with twice-weekly sessions follows, with further blood tests at 3 and 6 months to assess whether the improvement is sustained.

You may be eligible if you are 18 or older and have chronic fatigue associated with viral reactivation. People with electronic implants such as pacemakers, cochlear implants, or defibrillators, or those unable to commit to regular treatment sessions over 3 months, are not eligible.

Key Eligibility Criteria

Inclusion (1)

- adults with viral reactivated chronic fatigue

Exclusion (4)

- patients with electronic implants, e.g. pacemaker, defibrillator, cochlear implant, ring-shaped metals in the body
- planning to introduce new treatments during the study period
- unable to commit to regular treatment sessions over a 3 month period
- unable to give consent

Locations (1 total)

VIC, Australia

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12624000178549>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.